Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA583611
Max Phase: Preclinical
Molecular Formula: C25H42O4
Molecular Weight: 406.61
Molecule Type: Small molecule
Associated Items:
ID: ALA583611
Max Phase: Preclinical
Molecular Formula: C25H42O4
Molecular Weight: 406.61
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 23(S)-Methyl-Chenodeoxycholic Acid
Synonyms from Alternative Forms(1):
Canonical SMILES: C[C@H](C[C@H](C)C(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Standard InChI: InChI=1S/C25H42O4/c1-14(11-15(2)23(28)29)18-5-6-19-22-20(8-10-25(18,19)4)24(3)9-7-17(26)12-16(24)13-21(22)27/h14-22,26-27H,5-13H2,1-4H3,(H,28,29)/t14-,15+,16+,17-,18-,19+,20+,21-,22+,24+,25-/m1/s1
Standard InChI Key: XMIXAXLPZCFFCG-BQWNBIDXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 406.61 | Molecular Weight (Monoisotopic): 406.3083 | AlogP: 4.72 | #Rotatable Bonds: 4 |
Polar Surface Area: 77.76 | Molecular Species: ACID | HBA: 3 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.60 | CX Basic pKa: | CX LogP: 4.26 | CX LogD: 1.53 |
Aromatic Rings: 0 | Heavy Atoms: 29 | QED Weighted: 0.63 | Np Likeness Score: 2.47 |
1. Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B, Sardella R, Pruzanski M, Roda A, Pastorini E, Schoonjans K, Auwerx J.. (2009) Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity., 52 (24): [PMID:20014870] [10.1021/jm901390p] |
2. Yu DD, Sousa KM, Mattern DL, Wagner J, Fu X, Vaidehi N, Forman BM, Huang W.. (2015) Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists., 23 (7): [PMID:25735208] [10.1016/j.bmc.2015.01.048] |
3. Xu Y.. (2016) Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases., 59 (14): [PMID:26878262] [10.1021/acs.jmedchem.5b00342] |
Source(1):